Latest results from SHIGETECVAX to be presented at the VASE conference 2022
29 November 2022
The Vaccines Against Shigella and ETEC (VASE) Conference is an international gathering dedicated to developing Shigella and enterotoxigenic Escherichia coli (ETEC) vaccines. Hosted by PATH, a global non-profit organisation dedicated to achieving health equity, it’s an event for people like you who care about improving public health and saving lives by reducing diarrheal disease.
The latest results from EVI-coordinated SHIGETECVAX project funded by the European Commission under the Horizon 2020 Framework Programme will be presented at the VASE conference 2022 to be held in Washington on 29 November–01 December 2022. Dr Aicha Sayeh is representing EVI.
The safety and immunogenicity data of a combined Shigella/ETEC live attenuated vaccine candidate that was tested in a phase Ia clinical trial in Hungary will be presented by Eveliqure Biotechnologies Gmbh. Based on these encouraging results, a phase Ib trial in the endemic population in Bangladesh is being prepared by the project partners.